ERLEADA® (apalutamide)
Pivotal clinical trial publications
TITAN (Primary and Final Analysis)
- Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019a;381(1):13-24.
- Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021. 39(20):2294-2303.
SPARTAN (Primary and Final Analysis)
